Myokardia Inc (MYOK) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $-0.37 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.33. The company posted revenue of $3.55 million in the period, compared to analysts expectations of $5.16 million.
In a different news, on May 6, 2016, Anastasios Gianakakos (CEO) purchased 2,279 shares at $8.50 per share price. According to the SEC, on Nov 5, 2015, Jonathan C Fox (Chief Medical Officer) purchased 3,000 shares at $10.00 per share price. On Nov 5, 2015, Mark L Perry (director) purchased 5,000 shares at $10.00 per share price, according to the Form-4 filing with the securities and exchange commission.
MyoKardia Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). In addition the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.